Pharmacokinetics of Gefitinib Predicts Antitumor Activity for Advanced Non-small Cell Lung Cancer
Pharmacokinetics of Gefitinib Predicts Antitumor Activity for Advanced Non-small Cell Lung Cancer
复制标题
DOI：
10.1097/jto.0b013e3181e59a7b
复制
发表时间：
2010-09-01
影响因子：
20.4
通讯作者：
Kohno, Shigeru
中科院分区：
文献类型：
--
作者：
Nakamura, Yoichi;Sano, Kazumi;Kohno, Shigeru
我们评估了日本晚期非小细胞肺癌（NSCLC）患者血浆吉非替尼浓度与疗效之间的关系。方法：采用高效液相色谱法测定44例晚期NSCLC患者每日接受250 mg吉非替尼治疗的第3天（D3）和第8天（D8）吉非替尼血浆谷水平
Introduction: We assessed the relationship between the plasma concentration of gefitinib and its efficacy in Japanese patients with advanced non-small cell lung cancer (NSCLC)Methods: Plasma trough levels of gefitinib were measured on days 3 (D3) and 8 (D8) by high-performance liquid chromatography in 44 patients with advanced NSCLC treated with 250 mg gefitinib daily Eligibility criteria included performance status